FATE vs KEY · rev $13.6M vs P/E 13, rev $7.51B
Fate Therapeutics Inc (FATE) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
FATE currently screens at market cap $331.0M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the FATE and KEY stock pages for the full models.
Not investment advice.